NVCR News and Press, NovoCure Limited From 12/07/21

Novocure (NASDAQ:NVCR) signed a purchase and sale agreement to acquire and construct an office building at 64 Vaughan Mall, in the heart of downtown Portsmouth, New Hampshire. The purchase price of the property is $9.5M. On agreement closure, Novocure will enter into a construction ...

The property will provide space for Novocure’s growing workforce, and house a world-class training and development center Novocure (NASDAQ: NVCR) today announced that the company has signed a purchase and sale agreement to acquire and construct an office building at 6...

Novocure (NASDAQ: NVCR) today announced the 4 th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields...

They may be the companies behind some of the U.S.'s most compelling growth stock stories. But shares of NovoCure (NASDAQ: NVCR) , Pinterest (NYSE: PINS) , and MarketAxess (NASDAQ: MKTX) have been strangely poor performers this year, with prices down 46%, 39%, and 38%...

NovoCure (NASDAQ: NVCR) was one of the better-performing stocks of early 2021, but the big gains came to an end in June. Since peaking this summer, shares have lost more than 58% of their value. Is the recent plunge an opportunity to buy a great medical device stock on sale, or ...

Evercore ISI says that getting some feedback on particulars around one oncology company's fiscal 2020 led it to take a deeper dive into revenue drivers - and to slash revenue estimates for the coming years. That's NovoCure (NASDAQ:NVCR), and after noting that the company's fiscal year saw a b...

NVCR has an approved product targeting 3 indications, from which it generates revenue. It has a late-stage pipeline. If the pipeline matures, this could have huge revenue potential. For further details see: NovoCure: Threshold Of Greatness

Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in the 33 rd Annual 2021 Piper Sandler Healthcar...

Final data from LUNAR trial anticipated year-end 2022 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with immune checkpoint inhibitors or...

Median progression-free survival was at least 11.2 months in patients with greater than 9 months of follow-up Partial or complete response was detected in 24% of patients Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Onco...